

# europaean journal of gynaecological oncology

an International Journal

*Founding Editor*

**A. Onnis**

*Montréal (Canada)*

*Editors-in-Chief*

**M. Marchetti**

*Montréal (Canada)*

**P. Bószé**

*Budapest (Hungary)*

*Associate Editor*

**T. Maggino**

*Padua (Italy)*

*Assistant Editor*

**J. Wilson**

*San Diego - CA (USA)*

*Editorial Board*

Allen H.H., *London, Ontario (Canada)*

Ayhan A., *Ankara (Turkey)*

Balat O., *Graziantep (Turkey)*

Bănceanu G., *Bucarest (Romania)*

Basta A., *Krakow (Poland)*

Bender H.C., *Dusseldorf (Germany)*

Charkviani T., *Tbilisi (Georgia)*

Chiarelli S., *Padua (Italy)*

De Oliveira C.F., *Coimbra (Portugal)*

Dexeus S. Jr., *Barcelona (Spain)*

Di Paola G.R.,

*Buenos Aires (Argentina)*

Di Re F., *Milan (Italy)*

Di Saia P., *Orange, CA (USA)*

Elit L., *Hamilton (Canada)*

Friedrich M., *Krefeld (Germany)*

Geisler H.E., *Indianapolis, IN (USA)*

Gorins A., *Paris (France)*

Heintz A.P.M.,

*Utrecht (The Netherlands)*

Ioannidou-Mouzaka L.,

*Athens (Greece)*

Jordan J.A.,

*Birmingham, England (UK)*

Klastersky J., *Bruxelles (Belgium)*

Kubista E., *Vienna (Austria)*

Lee Y.S., *Daegu (South Korea)*

Markowska J., *Poznan (Poland)*

Marth C., *Innsbruck (Austria)*

Massuger Leon F.A.G.,

*Nijmegen (The Netherlands)*

Menczer J., *Savyon (Israel)*

Monsonogo J., *Paris (France)*

Pálfalvi L., *Budapest, (Hungary)*

Piura B., *Beer Sheva (Israel)*

Piver S.M., *Buffalo, NY (USA)*

Rakar S., *Ljubljana (Slovenia)*

Shepherd J.H.,

*London, England (UK)*

Smit B.J., *Tygerberg (South Africa)*

Stelmachów J., *Warsaw (Poland)*

Syrjänen K., *Turku (Finland)*

Tjalma W., *Antwerpen (Belgium)*

Ungár L., *Budapest (Hungary)*

Vermorken J.B., *Edegem (Belgium)*

Wang P.H., *Taipei (Taiwan)*

Winter R., *Graz (Austria)*

Yokoyama Y., *Hirosaki (Japan)*

*Publishing Organization (M. Morsani):*

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)

Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

*Editorial Office (M. Critelli):*

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

**DISTINGUISHED EXPERT SERIES**

- Robotic-assisted laparoscopic anterior pelvic exenteration in patients with advanced ovarian cancer: Farghaly's technique** 361  
 S.A. Farghaly - *New York, NY (USA)*  
 The safety and efficacy of robotic-assisted laparoscopy for anterior pelvic exenteration in patients with advanced ovarian cancer was evaluated.

**ORIGINAL ARTICLES**

- Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy** 364  
 T. Chiyoda, H. Tsuda, H. Nomura, F. Kataoka, E. Tominaga, A. Suzuki, N. Susumu, D. Aoki - *Tokyo, JAPAN*  
 The treatment-free interval from second-line chemotherapy may predict the survival benefit of third-line chemotherapy.
- Predictive factors for the detection of CIN II-III in the follow-up of women with CIN I** 369  
 E. Gonzalez-Bosquet, L. Selva, J. Sabria, L. Pallares, L. Almeida, C. Muñoz-Almagro, J.M. Lailla - *Esplugues, BARCELONA*  
 HPV infection and duration of follow-up are predictive factors for the detection of CIN II-III in follow-up care for women with CIN I.
- DNA cytometry as a first-line method for diagnosis of cervical precancer with respect to clinical behaviour** 372  
 O. Reich, M. Ballon - *Graz, AUSTRIA*  
 DNA-ICM should be used as an objective first-line diagnostic tool for predicting cervical precancer.
- Human telomerase RNA gene (TERC) gain and polysomy of chromosome 3 in cervicovaginal liquid-based pap preparations: a fluorescence in situ hybridization study** 375  
 W. Sui, M. Ou, J. Chen, J. Yu, Y. Zhang, H. Lan, H. Huang, Y. Dai - *Guangdong Province, REPUBLIC OF CHINA*  
 A FISH study indicates that TERC gain and polysomy 3 are associated with patients with CIN and SCCA in Guilin City, China.
- Prognostic significance of topoisomerase II alpha and collagen IV immunoexpression in cervical cancer** 380  
 Š. Smrkolj, M. Eržen, S. Rakar - *Ljubljana, SLOVENIA*  
 Immunohistochemical expression of topoisomerase IIalpha and collagen IV might complement the assessment of cervical cancer prognosis with appropriate choice of type and extent of treatment.
- Epigenetic therapy and cisplatin chemoradiation in FIGO Stage IIIB cervical cancer** 386  
 M. Candelaria, L. Cetina, E. Pérez-Cárdenas, E. de la Cruz-Hernández, A. González-Fierro, C. Trejo-Becerril, L. Taja-Chayeb, J. Chanona, D. Arias, A. Dueñas-González - *Mexico City, MEXICO*  
 Epigenetic agents hydralazine and valproate are well-tolerated and safe when administered with cisplatin chemoradiation in locally advanced cervical cancer.
- Loop electrosurgical excision procedure in Greek patients with vaginal intraepithelial neoplasia** 392  
 E. Terzakis, G. Androutopoulos, D. Zygouris, C. Grigoriadis, G. Derdelis, N. Arnogiannaki - *Athens, GREECE*  
 Electrosurgery on vaginal intraepithelial neoplasia.
- Clinical features of 215 Stage I ovarian tumors in Japanese women** 395  
 S. Kaku, N. Takeshima, K. Umayahara, R. Furuta, F. Akiyama, K. Takizawa - *Tokyo, JAPAN*  
 Stage I borderline ovarian tumors show low aggressiveness, while Stage Ic ovarian cancer and clear cell carcinoma are highly aggressive.
- Complications and obstetric outcomes after laser conization during pregnancy** 399  
 N. Seki, J. Kodama, T. Kusumoto, K. Nakamura, A. Hongo, Y. Hiramatsu - *Okayama, JAPAN*  
 Laser conization during pregnancy is feasible and comparable to cold knife conization and LEEP with regard to the rates of complication and obstetric outcome.

# Loop electrosurgical excision procedure in Greek patients with vaginal intraepithelial neoplasia

E. Terzakis<sup>1</sup>, G. Androutopoulos<sup>2</sup>, D. Zygouris<sup>1</sup>, C. Grigoriadis<sup>1</sup>, G. Derdelis<sup>1</sup>, N. Arnogiannaki<sup>3</sup>

<sup>1</sup>2<sup>nd</sup> Department of Gynaecology, St. Savvas Anticancer-Oncologic Hospital, Athens

<sup>2</sup>Department of Obstetrics and Gynaecology, Amfissa General Hospital, Amfissa

<sup>3</sup>Department of Pathology, St. Savvas Anticancer-Oncologic Hospital, Athens (Greece)

## Summary

**Objective:** The aim of our study was to evaluate the therapeutic effectiveness of the loop electrosurgical excision procedure (LEEP) in Greek patients with vaginal intraepithelial neoplasia (VAIN). **Materials and Methods:** Between January 2002 and January 2009, 23 women with histologically confirmed VAIN were included in our study. For the LEEP procedure we used a high frequency electrosurgery unit with at least 80 W output. **Results:** Complete response rate at 12 months of follow-up was 86.96%. Recurrence rate at 12 months of follow-up was 13.04%. Complete response rate at 24 months of follow-up was 75%. Recurrence rate at 24 months of follow-up was 25%. **Conclusion:** LEEP may constitute a valuable excisional method for the treatment of VAIN. It provides an interpretable specimen of the whole lesion within a few minutes. It needs a short period of training and has low cost.

**Key words:** Electrosurgery; LEEP; Vaginal intraepithelial neoplasia; VAIN.

## Introduction

Vaginal intraepithelial neoplasia (VAIN) is uncommon, accounting for approximately < 1% of lower genital tract intraepithelial neoplasia [1, 2]. However VAIN is now being diagnosed in younger women and this rise seems to be associated with the increased prevalence of human papilloma virus (HPV) infections of the lower genital tract [3].

Generally, most patients are asymptomatic. If present, symptoms may include postcoital spotting, vaginal bleeding, unusual vaginal discharge and odor [4, 5]. The majority of lesions located in the upper one-third of vagina and are often multifocal [4, 5].

The natural history of VAIN is thought to be similar to that of cervical intraepithelial neoplasia (CIN), with risk for progression to vaginal cancer [4]. In women with VAIN, 78% may regress, 13% may persist, and 9% may progress to invasive vaginal cancer [4].

The management of women with VAIN remains controversial. Treatment protocols use surgical procedures (local excision, partial vaginectomy, total vaginectomy, loop electrosurgical excision procedure (LEEP), laser CO<sub>2</sub> surgery), topical medical therapy (5% 5-fluorouracil) or radiation therapy [6-11].

The aim of our study was to evaluate the therapeutic effectiveness of LEEP in Greek patients with VAIN.

## Material and Methods

Between January 2002 and January 2009, about 23 women with histologically confirmed VAIN were referred to the 2<sup>nd</sup> Department of Gynecology of St. Savvas Anticancer-Oncologic

Hospital of Athens. Among them, nine were treated for CIN 3 and three were treated for microinvasive cervical carcinoma Stage Ia1.

LEEP was performed in the operating room, with the patient placed in the dorsal lithotomy position. For regional anesthesia we used 2% lidocaine solution diluted with normal saline (2:1), to infiltrate the vagina lesion and separate vaginal epithelium from underlying tissue.

In all women the lesional tissue was treated with LEEP, 3 mm away from lesion margins (2 mm for free lesion margins and 1 mm for thermal effect). The tissue specimen consisted of the vaginal mucosa and a portion of the submucosal tissue. Depth was controlled by performing procedures at high magnification.

For LEEP a high frequency electrosurgery unit was used with at least 80 W output. For electroexcision we used a 10 x 4 mm loop electrode and we selected blend cut mode with 50 W power output. For electrofulguration we used a 5 mm ball electrode and we selected blend coag mode with 60 W power output.

All patients were advised to avoid intercourse during the first four to six weeks following the procedure and return for follow-up at six weeks. The post-treatment follow-up protocol included physical examination, vaginal smear and colposcopic assessment at three, six, nine and 12 months for the first year, and yearly after.

Complete response was defined as no cytologic and colposcopic evidence of any VAIN lesion. Recurrence was defined as cytologic and colposcopic evidence of a new VAIN lesion in complete responders.

When patients had more than one grade of VAIN, they were assigned the highest grade. Patients with one focus of VAIN were identified as having unifocal and those with two or more areas were identified as having multifocal disease.

The study was approved by the Ethical Committee of the Hospital. Informed consent was obtained from each woman. Statistical analyses were performed using the SPSS-13 for Windows.

Revised manuscript accepted for publication March 8, 2010

**Results**

The median age at diagnosis of VAIN was 55 years (range 23-80 years). The median follow-up was 34.6 months (range 16-60 months). The demographics of women are shown in Table 1.

The median operating time was 15 min (range 10-20 min) depending on multifocal and extent of the lesion. The median healing time was five weeks (range 4-6 weeks) depending on the extent of the wound. All tissue specimens had free surgical margins. In our study population we had four VAIN 1, nine VAIN 2 and ten VAIN 3.

Complete response rate at 12 months of follow-up was 86.96%. Recurrence rate at 12 months of follow-up was 13.04%. Complete response rate at 24 months of follow-up was 75%. Recurrence rate at 24 months of follow-up was 25%. None of the treated patients progressed to invasive vaginal cancer during a mean follow-up of 34.6 months. These data are shown in Tables 2 and 3.

Table 1. — Women's demographics (n = 23).

		Number of patients (n = 23)	Percentage (%)
Age	< 40	2	8.69%
	40-60	15	65.22%
	> 60	6	26.09%
VAIN	VAIN 1	4	17.39%
	VAIN 2	9	39.13%
	VAIN 3	10	43.48%
History of CIN	Yes	9	39.13%
	No	14	60.87%
History of cervical cancer	Yes	3	13.04%
	No	20	86.96%
History of radiotherapy	Yes	0	0%
	No	23	100%
History of immunosuppression	Yes	0	0%
	No	23	100%

Table 2. — Response at 12 months of follow-up (n = 23).

	Complete response	Recurrence
VAIN 1 (n = 4)	4 (100%)	0 (0%)
VAIN 2 (n = 9)	8 (88.89%)	1 (11.11%)
VAIN 3 (n = 10)	8 (80%)	2 (20%)
Total	20 (86.96%)	3 (13.04%)

Table 3. — Response at 24 months of follow-up (n = 16).

	Complete response	Recurrence
VAIN 1 (n = 2)	2 (100%)	0 (0%)
VAIN 2 (n = 6)	5 (83.33%)	1 (16.67%)
VAIN 3 (n = 8)	5 (62.5%)	3 (37.5%)
Total	12 (75%)	4 (25%)

**Discussion**

Vaginal intraepithelial neoplasia (VAIN) has histopathology similar to cervical intraepithelial neoplasia (CIN) [12]. VAIN development, following HPV infection, may require a greater period of time and may occur less frequently because of the different type of epithelium from which VAIN arises [13]. The vagina lacks an active transformation zone with immature epithelial cells sus-

ceptible to HPV infection. However, HPV entry may result from vaginal mucosal abrasions (from coitus or tampon use) and reparative metaplastic squamous cell activity [12].

VAIN may occur as an isolated lesion or as a lesion on the vaginal vault after hysterectomy for CIN or invasive cervical carcinoma [4, 14]. Most VAIN lesions occur in women with a history of CIN or invasive cervical carcinoma [6, 15]. These lesions may arise at the same time (synchronous lesions) or up to several years after the initial CIN lesion (metachronous lesions) [16]. The time interval from an initial diagnosis of CIN 3 to a current diagnosis of VAIN 3 varies from two to 17 years [17]. In our study 11 patients had an isolated VAIN lesion, nine patients had a VAIN lesion on the vaginal vault after hysterectomy for CIN 3 and three patients had VAIN lesions on the vaginal vault after hysterectomy for microinvasive cervical carcinoma Stage 1a1.

The majority of VAIN lesions occur in the upper one-third of vagina. The middle and lower thirds of vagina are involved by less than 10% of lesions [6]. The majority of VAIN are also multifocal [4, 6, 17]. In our study, all women had VAIN lesions in the upper one-third of the vagina. Among them, 13 women had unifocal VAIN lesions and ten women had multifocal VAIN lesions.

Risk factors for developing VAIN are low education, low family income, previous abnormal Papanicolaou smear, genital warts, CIN or cervical cancer, immunosuppression, radiation therapy and history of diethylstilbestrol exposure [18]. In our study nine patients had been treated for CIN 3 and three patients had been treated for microinvasive cervical carcinoma Stage 1a1. None of the women had any history of immunosuppression, radiation therapy or diethylstilbestrol exposure.

Vaginal intraepithelial neoplasia is a rare disorder that, in most instances, will regress after initial treatment. However, patients with VAIN require careful monitoring because of the risk of recurrence and even progression to invasion [4, 5]. Risk factors for recurrence of VAIN include multifocality, association with neoplasia on other anogenital sites, histologic grade, immunosuppression and treatment modality [4-6]. In our study three women treated for VAIN 3 and one woman treated for VAIN 2 recurred after initial treatment. None of the women in our study progressed to invasive vaginal cancer during a mean follow-up of 34.6 months.

The choice of treatment modality for patients with VAIN is influenced by the number of lesions, location of lesions, length of vagina, sexual activity, previous radiation therapy, previous VAIN treatment, patient preference and operator experience [6, 19]. Multifocal lesions are more difficult to treat because some lesions could be missed during treatment [6].

LEEP for VAIN lesions has been proposed with excellent results in selected groups of patients [6, 8, 9]. There are potential advantages of LEEP for treating VAIN lesions which include low cost of equipment, avoidance of the operating room, avoidance of general anesthesia, limited tissue damage, provision of a specimen, reduced

bleeding and reduced discomfort [8, 9]. LEEP may be more accurate than laser CO2 in uncovering foci of early invasion (LEEP uses excision rather than ablation) [9]. In our study all tissue specimens had free surgical margins. The operating time ranged between 10-20 min depending on multifocal and extent of the lesion. We believe that every gynecologist is capable of performing LEEP on VAIN after 10-15 supervised applications with a high index of confidence.

There are potential complications of LEEP for treating VAIN lesions which include bleeding, infection, vaginal perforation, bladder injury, rectal injury, vesicovaginal and rectovaginal fistulae [8, 9, 20, 21]. In our study population, there were no complications. Only in a few cases did spot bleeding occur during surgery. The newly formed vaginal epithelium, after a mean period of five weeks, presents excellent topography. None of the women complained of post-treatment sexual dysfunction.

It is clear that current treatments for VAIN are suboptimal and continue to represent a clinical challenge. The best approach is individualized management based on clinical presentation, extent of disease and patient preference. LEEP may constitute a valuable excisional method for the treatment of VAIN. It provides an interpretable specimen of the whole lesion within a few minutes. It needs a short period of training and has low cost.

## References

- [1] Sillman F.H., Sedlis A., Boyce J.G.: "A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil" (review). *Obstet. Gynecol. Surv.*, 1985, 40, 190.
- [2] Timonen S., Numers C., Meyer B.: "Dysplasia of the vaginal epithelium". *Gynaecologia*, 1966, 162, 125.
- [3] Sugase M., Matsukura T.: "Distinct manifestations of human papillomaviruses in the vagina". *Int. J. Cancer*, 1997, 72, 412.
- [4] Aho M., Vesterinen E., Meyer B., Purola E., Paavonen J.: "Natural history of vaginal intraepithelial neoplasia". *Cancer*, 1991, 68, 195.
- [5] Sillman F.H., Fruchter R.G., Chen Y.S., Camilien L., Sedlis A., McTigue E.: "Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management". *Am. J. Obstet. Gynecol.*, 1997, 176, 93.
- [6] Dodge J.A., Eltabbakh G.H., Mount S.L., Walker R.P., Morgan A.: "Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia". *Gynecol. Oncol.*, 2001, 83, 363.
- [7] Diakomanolis E., Rodolakis A., Boulgaris Z., Blachos G., Michalakis S.: "Treatment of vaginal intraepithelial neoplasia with laser ablation and upper vaginectomy". *Gynecol. Obstet. Invest.*, 2002, 54, 17.
- [8] Patsner B.: "Treatment of vaginal dysplasia with loop excision: report of five cases". *Am. J. Obstet. Gynecol.*, 1993, 169, 179.
- [9] Fanning J., Manahan K.J., McLean S.A.: "Loop electrosurgical excision procedure for partial upper vaginectomy". *Am. J. Obstet. Gynecol.*, 1999, 181, 1382.
- [10] Krebs H.B., Helmkamp B.F.: "Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions". *Obstet. Gynecol.*, 1991, 78, 205.
- [11] Woodman C.B., Mould J.J., Jordan J.A.: "Radiotherapy in the management of vaginal intraepithelial neoplasia after hysterectomy". *Br. J. Obstet. Gynaecol.*, 1988, 95, 976.
- [12] Woodruff J.D.: "Carcinoma in situ of the vagina". *Clin. Obstet. Gynecol.*, 1981, 24, 485.
- [13] Androutsopoulos G., Adonakis G., Ravazoula P., Kourounis G.: "Vaginal cancer in patient treated for cervical intraepithelial neoplasia (CIN 3): a case report". *Eur. J. Gynaecol. Oncol.*, 2006, 27, 638.
- [14] Diakomanolis E., Stefanidis K., Rodolakis A., Haidopoulos D., Sindos M., Chatzipappas I., Michalakis S.: "Vaginal intraepithelial neoplasia: report of 102 cases" (review). *Eur. J. Gynaecol. Oncol.*, 2002, 23, 457.
- [15] Rome R.M., England P.G.: "Management of vaginal intraepithelial neoplasia: a series of 132 cases with long-term follow-up". *Int. J. Gynecol. Cancer*, 2000, 10, 382.
- [16] Vinokurova S., Wentzensen N., Einenkel J., Klaes R., Ziegert C., Melsheimer P. et al.: "Clonal history of papillomavirus-induced dysplasia in the female lower genital tract". *J. Natl. Cancer Inst.*, 2005, 97, 1816.
- [17] Hummer W.K., Mussey E., Decker D.G., Dockerty M.B.: "Carcinoma in situ of the vagina". *Am. J. Obstet. Gynecol.*, 1970, 108, 1109.
- [18] Brinton L.A., Nasca P.C., Mallin K., Schairer C., Rosenthal J., Rothenberg R. et al.: "Case-control study of in situ and invasive carcinoma of the vagina". *Gynecol. Oncol.*, 1990, 38, 49.
- [19] Indermaur M.D., Martino M.A., Fiorica J.V., Roberts W.S., Hoffman M.S.: "Upper vaginectomy for the treatment of vaginal intraepithelial neoplasia". *Am. J. Obstet. Gynecol.*, 2005, 193, 577.
- [20] Harroch J., Siegler E., Bornstein J.: "Vesicovaginal fistula resulting from loop electrosurgical excision in a woman with intraepithelial neoplasia of the cervix and vagina: a case report". *J. Low Genit. Tract. Dis.*, 2004, 8, 205.
- [21] Powell J.L., Asbery D.S.: "Treatment of vaginal dysplasia: just a simple loop electrosurgical excision procedure?". *Am. J. Obstet. Gynecol.*, 2000, 182, 731.

Address reprint requests to:  
G. ANDROUTSOPOULOS, M.D.  
Anaxagora 45  
Ag. Paraskeui  
15343 (Greece)  
e-mail: androutsopoulosgeorgios@hotmail.com